U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H24N4O2.2C2H6O4S
Molecular Weight 592.683
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PENTAMIDINE ISETHIONATE

SMILES

OCCS(O)(=O)=O.OCCS(O)(=O)=O.NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1

InChI

InChIKey=YBVNFKZSMZGRAD-UHFFFAOYSA-N
InChI=1S/C19H24N4O2.2C2H6O4S/c20-18(21)14-4-8-16(9-5-14)24-12-2-1-3-13-25-17-10-6-15(7-11-17)19(22)23;2*3-1-2-7(4,5)6/h4-11H,1-3,12-13H2,(H3,20,21)(H3,22,23);2*3H,1-2H2,(H,4,5,6)

HIDE SMILES / InChI

Molecular Formula C2H6O4S
Molecular Weight 126.132
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C19H24N4O2
Molecular Weight 340.4195
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: http://www.drugbank.ca/drugs/DB00738 https://en.wikipedia.org/wiki/Pentamidine

Pentamidine (formulated as a salt, pentamidine diisethionate or dimesilate) is an antimicrobial medication given for prevention and treatment of pneumocystis pneumonia (PCP) caused by Pneumocystis jirovecii (formerly known as Pneumocystis carinii), a severe interstitial type of pneumonia often seen in patients with HIV infection. The drug is also the mainstay of treatment for stage I infection with Trypanosoma bruceigambiense (West African trypanosomiasis). Pentamidine is also used as a prophylactic against PCP in patients receiving chemotherapy and in some patients who have undergone organ transplantation, as they also have a depressed immune system as a direct side-effect of the drugs used. The mortality of untreated PCP is very high. Additionally, pentamidine has good clinical activity in treating leishmaniasis, and yeast infections caused by the organism Candida albicans. Pentamidine is also used as a prophylactic antibiotic for children undergoing treatment for leukemia. Studies suggest that the pentamidine isethionate interferes with microbial nuclear metabolism by inhibition of DNA, RNA, phospholipid and protein synthesis. However, the mode of action is not fully understood.

CNS Activity

Curator's Comment: Pentamidine is able to cross the BBB, but a proportion is retained within the capillary endothelium. This may well explain its inability to treat well established CNS trypanosome infection. Furthermore, pentamidine movement into the CNS is a complex process involving multiple transporters.

Originator

Curator's Comment: Pentamidine was first discovered by Ewins et al., as shown in U.S. Patent No. 2,277,861

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: O14717
Gene ID: 1787.0
Gene Symbol: TRDMT1
Target Organism: Homo sapiens (Human)
204.4 µM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
NEBUPENT

Approved Use

Pentamidine

Launch Date

4.82112012E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
751 nM
3.9 mg/kg 1 times / day multiple, intravenous
dose: 3.9 mg/kg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
PENTAMIDINE blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
18.8 ng/mL
4 mg/kg 1 times / day multiple, irrigation
dose: 4 mg/kg
route of administration: Irrigation
experiment type: MULTIPLE
co-administered:
PENTAMIDINE unknown
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
612 ng/mL
4 mg/kg single, intravenous
dose: 4 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PENTAMIDINE unknown
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
6734 nM × h
3.9 mg/kg 1 times / day multiple, intravenous
dose: 3.9 mg/kg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
PENTAMIDINE blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
6.4 h
4 mg/kg single, intravenous
dose: 4 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PENTAMIDINE unknown
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1600 mg single, intravenous
Overdose
unhealthy, 17
n = 1
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Age Group: 17
Population Size: 1
Sources:
Other AEs: Impaired renal function, Hepatic impairment...
Other AEs:
Impaired renal function
Hepatic impairment
Hypotension
Cardiopulmonary arrest
Sources:
600 mg 1 times / month multiple, respiratory
Highest studied dose
Dose: 600 mg, 1 times / month
Route: respiratory
Route: multiple
Dose: 600 mg, 1 times / month
Sources: Page: p.1167
unhealthy, 37.9 ± 7.5
n = 76
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Age Group: 37.9 ± 7.5
Sex: M+F
Population Size: 76
Sources: Page: p.1167
300 mg 1 times / month multiple, respiratory
Recommended
Dose: 300 mg, 1 times / month
Route: respiratory
Route: multiple
Dose: 300 mg, 1 times / month
Sources: Page: p.6
unhealthy
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Sources: Page: p.6
Disc. AE: Acute pancreatitis...
AEs leading to
discontinuation/dose reduction:
Acute pancreatitis
Sources: Page: p.6
4 mg/kg 1 times / day multiple, intramuscular
Recommended
Dose: 4 mg/kg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 4 mg/kg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Sources:
Disc. AE: Hypotension, Hypoglycemia...
Other AEs: Extravasation, Injection site ulceration...
AEs leading to
discontinuation/dose reduction:
Hypotension (grade 3-5)
Hypoglycemia (grade 5)
Acute pancreatitis (grade 5)
Cardiac arrhythmias (grade 5)
Cardiac arrhythmias (grade 5)
Other AEs:
Extravasation
Injection site ulceration
Injection site necrosis
Slough injection site
Sources:
4 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 4 mg/kg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Sources:
Disc. AE: Hypotension, Hypoglycemia...
Other AEs: Extravasation, Injection site ulceration...
AEs leading to
discontinuation/dose reduction:
Hypotension (grade 3-5)
Hypoglycemia (grade 5)
Acute pancreatitis (grade 5)
Cardiac arrhythmias (grade 5)
Cardiac arrhythmias (grade 5)
Other AEs:
Extravasation
Injection site ulceration
Injection site necrosis
Slough injection site
Sources:
AEs

AEs

AESignificanceDosePopulation
Cardiopulmonary arrest
1600 mg single, intravenous
Overdose
unhealthy, 17
n = 1
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Age Group: 17
Population Size: 1
Sources:
Hepatic impairment
1600 mg single, intravenous
Overdose
unhealthy, 17
n = 1
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Age Group: 17
Population Size: 1
Sources:
Hypotension
1600 mg single, intravenous
Overdose
unhealthy, 17
n = 1
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Age Group: 17
Population Size: 1
Sources:
Impaired renal function
1600 mg single, intravenous
Overdose
unhealthy, 17
n = 1
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Age Group: 17
Population Size: 1
Sources:
Acute pancreatitis Disc. AE
300 mg 1 times / month multiple, respiratory
Recommended
Dose: 300 mg, 1 times / month
Route: respiratory
Route: multiple
Dose: 300 mg, 1 times / month
Sources: Page: p.6
unhealthy
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Sources: Page: p.6
Extravasation
4 mg/kg 1 times / day multiple, intramuscular
Recommended
Dose: 4 mg/kg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 4 mg/kg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Sources:
Injection site necrosis
4 mg/kg 1 times / day multiple, intramuscular
Recommended
Dose: 4 mg/kg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 4 mg/kg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Sources:
Injection site ulceration
4 mg/kg 1 times / day multiple, intramuscular
Recommended
Dose: 4 mg/kg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 4 mg/kg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Sources:
Slough injection site
4 mg/kg 1 times / day multiple, intramuscular
Recommended
Dose: 4 mg/kg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 4 mg/kg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Sources:
Hypotension grade 3-5
Disc. AE
4 mg/kg 1 times / day multiple, intramuscular
Recommended
Dose: 4 mg/kg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 4 mg/kg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Sources:
Acute pancreatitis grade 5
Disc. AE
4 mg/kg 1 times / day multiple, intramuscular
Recommended
Dose: 4 mg/kg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 4 mg/kg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Sources:
Cardiac arrhythmias grade 5
Disc. AE
4 mg/kg 1 times / day multiple, intramuscular
Recommended
Dose: 4 mg/kg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 4 mg/kg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Sources:
Cardiac arrhythmias grade 5
Disc. AE
4 mg/kg 1 times / day multiple, intramuscular
Recommended
Dose: 4 mg/kg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 4 mg/kg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Sources:
Hypoglycemia grade 5
Disc. AE
4 mg/kg 1 times / day multiple, intramuscular
Recommended
Dose: 4 mg/kg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 4 mg/kg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Sources:
Extravasation
4 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 4 mg/kg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Sources:
Injection site necrosis
4 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 4 mg/kg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Sources:
Injection site ulceration
4 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 4 mg/kg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Sources:
Slough injection site
4 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 4 mg/kg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Sources:
Hypotension grade 3-5
Disc. AE
4 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 4 mg/kg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Sources:
Acute pancreatitis grade 5
Disc. AE
4 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 4 mg/kg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Sources:
Cardiac arrhythmias grade 5
Disc. AE
4 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 4 mg/kg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Sources:
Cardiac arrhythmias grade 5
Disc. AE
4 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 4 mg/kg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Sources:
Hypoglycemia grade 5
Disc. AE
4 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 4 mg/kg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer




Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes [IC50 0.097 uM]
yes
Drug as victim
PubMed

PubMed

TitleDatePubMed
Efficacy of trimethoprim and sulfamethoxazole in the prevention and treatment of Pneumocystis carinii pneumonitis.
1974 Mar
[Kidney failure during treatment of T. rhodesiense trypanosomiasis with pentamidin].
1977
Pentamidine treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Association with acute renal failure and myoglobinuria.
1985 Dec
Extrapyramidal symptoms in AIDS patients given low-dose metoclopramide or chlorpromazine.
1985 Nov 23
Pentamidine-associated hypotension and route of administration.
1985 Sep
Pentamidine and renal toxicity.
1985 Sep 12
Pentamidine and hematuria.
1986 Jul
Adverse reactions associated with pentamidine isethionate in AIDS patients: recommendations for monitoring therapy.
1986 Nov
Torsade de pointes during administration of pentamidine isethionate.
1987 Sep
Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective, noncrossover study.
1988 Aug 15
Ventricular tachycardia due to pentamidine isethionate.
1988 May
Torsades de pointes during intravenous pentamidine isethionate therapy.
1989 Jan 15
Renal insufficiency with nebulised pentamidine.
1989 Oct 28
Nephrotoxicity and hyperkalemia in patients with acquired immunodeficiency syndrome treated with pentamidine.
1989 Sep
Pentamidine-induced torsades de pointes in a renal transplant recipient with Pneumocystis carinii pneumonia.
1990 Apr
Structure-activity relationships of analogs of pentamidine against Plasmodium falciparum and Leishmania mexicana amazonensis.
1990 Jul
Reye's syndrome in adult with AIDS.
1990 Jun 16
Ventricular tachycardia and torsades de pointes complicating pentamidine therapy of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome.
1990 Oct 1
Pentamidine-associated nephrotoxicity and hyperkalemia in patients with AIDS.
1991 Nov
Anti-cryptosporidial drug activity screened with an immunosuppressed rat model.
1991 Nov-Dec
Inhibition of topoisomerases from Pneumocystis carinii by aromatic dicationic molecules.
1991 Nov-Dec
[Infantile visceral leishmaniasis in Morocco. A review of 67 cases managed at the Rabat Hospital for children (1979-1988)].
1991 Sep
High pentamidine levels associated with hypoglycemia and azotemia in a patient with Pneumocystis carinii pneumonia.
1992 Aug
Prolonged recurrence of pentamidine-induced torsades de pointes.
1992 Nov
Torsade de pointes after inhaled pentamidine.
1992 Nov
Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs.
1992 Sep
A reverse turn structure induced by a D,L-alpha-aminoxy acid dimer.
2003 Nov 26
Novel bisbenzamidines as potential drug candidates for the treatment of Pneumocystis carinii pneumonia.
2004 Sep 6
A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system.
2005 Feb
Pentamidine-induced long QT syndrome and block of hERG trafficking.
2005 Jan
Detection of immunotoxicity using T-cell based cytokine reporter cell lines ("Cell Chip").
2005 Jan 15
Pentamidine is an antiparasitic and apoptotic drug that selectively modifies ubiquitin.
2005 Oct
Use of Leishmania donovani field isolates expressing the luciferase reporter gene in in vitro drug screening.
2005 Sep
In vitro selection and in vivo efficacy of piperazine- and alkanediamide-linked bisbenzamidines against Pneumocystis pneumonia in mice.
2006 Jul
Novel synthesis of nicotinamide derivatives of cytotoxic properties.
2006 Jul 1
Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs.
2006 Mar
[Cutaneous leishmaniasis--an import from Belize].
2007
Perioral numbness associated with intravenous pentamidine administration.
2007 Jan
Cellulose biosynthesis pathway is a potential target in the improved treatment of Acanthamoeba keratitis.
2007 May
Using the zebrafish lateral line to screen for ototoxicity.
2008 Jun
Pentamidine dosage: a base/salt confusion.
2008 May 28
Effects of acute intravenous administration of pentamidine, a typical hERG-trafficking inhibitor, on the cardiac repolarization process of halothane-anesthetized dogs.
2009 Aug
Two cases of visceral leishmaniasis in Colombia resistant to meglumine antimonial treatment.
2009 Jul-Aug
Identification of human Ether-à-go-go related gene modulators by three screening platforms in an academic drug-discovery setting.
2010 Dec
Bisbenzamidine derivative, pentamidine represses DNA damage response through inhibition of histone H2A acetylation.
2010 Feb 9
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
2011 Jul 14
The pharmacological profile of brain liver intestine Na+ channel: inhibition by diarylamidines and activation by fenamates.
2011 Nov
Synthesis and antiprotozoal activities of benzyl phenyl ether diamidine derivatives.
2013 Sep
Utilization of human nuclear receptors as an early counter screen for off-target activity: a case study with a compendium of 615 known drugs.
2015 Jun
Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.
2015 May 18
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: 300 mg once every four weeks administered via the Respirgard
The recommended adult dosage is 300 mg once every four weeks administered via the Respirgard® II nebulizer. The dose should be delivered until the nebulizer chamber is empty (approximately 30 to 45 minutes). The flow rate should be 5 to 7 liters per minute from a 40 to 50 pounds per square inch (PSI) air or oxygen source. Alternatively, a 40 to 50 PSI air compressor can be used with flow limited by setting the flowmeter at 5 to 7 liters per minute or by setting the pressure at 22 to 25 PSI. Low pressure (less than 20 PSI) compressors should not be used.
Route of Administration: Irrigation
In Vitro Use Guide
Pentamidine was found to be active against T. whipplei strains both in axenic medium and in cell culture, with minimum inhibitory concentration ranges of 0.125-0.25mg/L.
Substance Class Chemical
Created
by admin
on Wed Jul 05 22:48:54 UTC 2023
Edited
by admin
on Wed Jul 05 22:48:54 UTC 2023
Record UNII
V2P3K60DA2
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PENTAMIDINE ISETHIONATE
MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN  
Official Name English
PENTAMIDINE DIISETIONATE [EP MONOGRAPH]
Common Name English
NEBUPENT
Brand Name English
PENTAMIDINE ISETHIONATE [USP MONOGRAPH]
Common Name English
Pentamidine isethionate [WHO-DD]
Common Name English
PENTAMIDINE ISETIONATE
JAN   MART.   WHO-IP  
Common Name English
PENTAMIDINE ISETHIONATE [ORANGE BOOK]
Common Name English
MB 800
Code English
PENTAMIDINE DIISETIONATE
EP  
Common Name English
PENTAMIDINE BIS(2-HYDROXYETHANESULFONATE)
Common Name English
PENTAMIDINE ISETIONATE [MART.]
Common Name English
PENTAMIDINE ISETIONATE [WHO-IP]
Common Name English
PENTAMIDINE ISETHIONATE [MI]
Common Name English
NSC-757400
Code English
RP 2512
Code English
ETHANESULFONIC ACID, 2-HYDROXY-, COMPD. WITH 4,4'-(1,5-PENTANEDIYLBIS(OXY))BIS (BENZENECARBOXIMIDAMIDE)
Common Name English
4,4'-(PENTANE-1,5-DIYLBIS(OXY))DIBENZIMIDAMIDE BIS(2-HYDROXYETHANESULPHONATE)
Systematic Name English
4,4'-(PENTANE-1,5-DIYLBIS(OXY))DIBENZIMIDAMIDE BIS(2-HYDROXYETHANESULFONATE)
Systematic Name English
PENTAMIDINE ISETIONATE [JAN]
Common Name English
PENTACARINAT
Brand Name English
NSC-620107
Code English
PENTAMIDINE ISETHIONATE [USP-RS]
Common Name English
OCZ103-OS
Code English
PENTAMIDINE ISETHIONATE [VANDF]
Common Name English
PENTAMIDINE ISETHIONATE [USAN]
Common Name English
PENTAMIDINI ISETIONAS [WHO-IP LATIN]
Common Name English
PENTAMIDINE DIISETIONATE [EP IMPURITY]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C277
Created by admin on Wed Jul 05 22:48:54 UTC 2023 , Edited by admin on Wed Jul 05 22:48:54 UTC 2023
FDA ORPHAN DRUG 1083
Created by admin on Wed Jul 05 22:48:54 UTC 2023 , Edited by admin on Wed Jul 05 22:48:54 UTC 2023
WHO-ATC P01CX01
Created by admin on Wed Jul 05 22:48:54 UTC 2023 , Edited by admin on Wed Jul 05 22:48:54 UTC 2023
FDA ORPHAN DRUG 21187
Created by admin on Wed Jul 05 22:48:54 UTC 2023 , Edited by admin on Wed Jul 05 22:48:54 UTC 2023
FDA ORPHAN DRUG 3784
Created by admin on Wed Jul 05 22:48:54 UTC 2023 , Edited by admin on Wed Jul 05 22:48:54 UTC 2023
FDA ORPHAN DRUG 25887
Created by admin on Wed Jul 05 22:48:54 UTC 2023 , Edited by admin on Wed Jul 05 22:48:54 UTC 2023
NCI_THESAURUS C514
Created by admin on Wed Jul 05 22:48:54 UTC 2023 , Edited by admin on Wed Jul 05 22:48:54 UTC 2023
Code System Code Type Description
MERCK INDEX
M8497
Created by admin on Wed Jul 05 22:48:54 UTC 2023 , Edited by admin on Wed Jul 05 22:48:54 UTC 2023
PRIMARY Merck Index
RXCUI
7995
Created by admin on Wed Jul 05 22:48:54 UTC 2023 , Edited by admin on Wed Jul 05 22:48:54 UTC 2023
PRIMARY RxNorm
RS_ITEM_NUM
1504900
Created by admin on Wed Jul 05 22:48:54 UTC 2023 , Edited by admin on Wed Jul 05 22:48:54 UTC 2023
PRIMARY
EPA CompTox
DTXSID5023796
Created by admin on Wed Jul 05 22:48:54 UTC 2023 , Edited by admin on Wed Jul 05 22:48:54 UTC 2023
PRIMARY
DRUG BANK
DBSALT000967
Created by admin on Wed Jul 05 22:48:54 UTC 2023 , Edited by admin on Wed Jul 05 22:48:54 UTC 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
PENTAMIDINE ISETHIONATE
Created by admin on Wed Jul 05 22:48:54 UTC 2023 , Edited by admin on Wed Jul 05 22:48:54 UTC 2023
PRIMARY Description: A white, or almost white, crystalline powder; odourless. Solubility: Soluble in 10 parts of water; slightly soluble in ethanol (~750 g/L) TS; practically insoluble in ether R. Category: Antipneumocystosis, antitoxoplasmosis and antitrypanosomal activity. Storage: Pentamidine isetionate should be kept in a well-closed container. Additional information: Pentamidine isetionate is hygroscopic and exhibits polymorphism. Definition: Pentamidine isetionate contains not less than 98.5% and not more than 102.5% of C19H24N4O2,2C2H6O4S, calculatedwith reference to the dried substance.
SMS_ID
100000079776
Created by admin on Wed Jul 05 22:48:54 UTC 2023 , Edited by admin on Wed Jul 05 22:48:54 UTC 2023
PRIMARY
NCI_THESAURUS
C29349
Created by admin on Wed Jul 05 22:48:54 UTC 2023 , Edited by admin on Wed Jul 05 22:48:54 UTC 2023
PRIMARY
DAILYMED
V2P3K60DA2
Created by admin on Wed Jul 05 22:48:54 UTC 2023 , Edited by admin on Wed Jul 05 22:48:54 UTC 2023
PRIMARY
FDA UNII
V2P3K60DA2
Created by admin on Wed Jul 05 22:48:54 UTC 2023 , Edited by admin on Wed Jul 05 22:48:54 UTC 2023
PRIMARY
EVMPD
SUB14795MIG
Created by admin on Wed Jul 05 22:48:54 UTC 2023 , Edited by admin on Wed Jul 05 22:48:54 UTC 2023
PRIMARY
ChEMBL
CHEMBL55
Created by admin on Wed Jul 05 22:48:54 UTC 2023 , Edited by admin on Wed Jul 05 22:48:54 UTC 2023
PRIMARY
NSC
620107
Created by admin on Wed Jul 05 22:48:54 UTC 2023 , Edited by admin on Wed Jul 05 22:48:54 UTC 2023
PRIMARY
USAN
TT-72
Created by admin on Wed Jul 05 22:48:54 UTC 2023 , Edited by admin on Wed Jul 05 22:48:54 UTC 2023
PRIMARY
ECHA (EC/EINECS)
205-424-1
Created by admin on Wed Jul 05 22:48:54 UTC 2023 , Edited by admin on Wed Jul 05 22:48:54 UTC 2023
PRIMARY
CHEBI
7977
Created by admin on Wed Jul 05 22:48:54 UTC 2023 , Edited by admin on Wed Jul 05 22:48:54 UTC 2023
PRIMARY
NSC
757400
Created by admin on Wed Jul 05 22:48:54 UTC 2023 , Edited by admin on Wed Jul 05 22:48:54 UTC 2023
PRIMARY
CAS
140-64-7
Created by admin on Wed Jul 05 22:48:54 UTC 2023 , Edited by admin on Wed Jul 05 22:48:54 UTC 2023
PRIMARY
PUBCHEM
8813
Created by admin on Wed Jul 05 22:48:54 UTC 2023 , Edited by admin on Wed Jul 05 22:48:54 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY